Complicated urinary tract infections (cUTIs) , particularly those involving ESBL-producing Gram-negative pathogens , continue to challenge clinicians worldwide due to rising resistance patterns and treatment failures. 1,2 Increasing dependence on carbapenems has further accelerated antimicrobial resistance, underscoring the need for effective, carbapenem-sparing alternatives that ensure durable microbiological and clinical cure. Explore our infographic to understand why Cefepime–Enmetazobactam is emerging as a compelling first-line option in cUTI , including acute pyelonephritis.
The combination offers broad ESBL/AmpC coverage 3 , compatible pharmacokinetics with high urinary excretion 4 , and demonstrated superiority in key clinical endpoints versus Piperacillin–Tazobactam, as evidenced by the global phase 3 ALLIUM Study 7 . With multiple regulatory approvals across regions 5,6 , this…
